Abstract
BackgroundAspirin is commonly used as the only pharmacologic agent for prevention of venous thromboembolism (VTE) after joint replacement surgery in the United States. Despite this, prospective studies investigating VTE events after aspirin‐only thromboprophylaxis in joint replacement surgery are lacking in the real‐world setting. ObjectivesThe aim of this study was to estimate the risk of VTE with aspirin‐only pharmacologic prophylaxis following joint replacement surgery. MethodsWe carried out a prospective observational study of 350 low‐risk patients (no prior history of VTE and low cardiovascular risk factors) who underwent total knee and total hip arthroplasty and received only aspirin for thromboprophylaxis postoperatively. ResultsThe observed risk of symptomatic VTE was 1.7% (95% confidence interval, 0.9%‐3.3%) over 3 months of follow up, with only one major bleeding event and no surgical hematomas. ConclusionThe risk of VTE with aspirin monotherapy for thromboprophylaxis in joint replacement surgery in this real‐world cohort was higher than previously reported.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research and Practice in Thrombosis and Haemostasis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
